EUCTR2014-005529-11-IE进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH)
ltragenyx Pharmaceutical Inc.0 个研究点目标入组 134 人开始时间: 2015年9月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 134
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Individuals eligible to participate in this study must meet all of the following criteria:
- •1) Male or female, aged 18 – 65 years, inclusive
- •2) Diagnosis of XLH supported by classic clinical features of adult XLH (such as short stature or bowed legs) and at least ONE of the following at Screening:
- •Documented PHEX mutation in either the patient, or in a directly related family member with appropriate X-linked inheritance
- •Serum iFGF23 level > 30 pg/mL by Kainos assay
- •3) Biochemical findings consistent with XLH at Screening Visit 2 following overnight fasting (min. 8 hours):
- •Serum phosphorus < 2.5 mg/dL (0.81 mmol/L)
- •TmP/GFR of < 2.5 mg/dL
- •4) Presence of skeletal pain attributed to XLH/osteomalacia, as defined by a score of = 4 on the Brief Pain Inventory question 3 (BPI-Q3, Worst Pain) at Screening Visit 1. (Skeletal pain that, in the opinion of the investigator, is attributed solely to causes other than XLH/osteomalacia—for example, back pain or joint pain in the presence of severe osteoarthritis by radiograph in that anatomical location—in the absence of any skeletal pain likely attributed to XLH/osteomalacia should not be considered for eligibility)
- •5) Estimated glomerular filtration rate (eGFR) = 60 mL/min (using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation) or eGFR of 45-60 mL/min at Screening Visit 2 with confirmation that the renal insufficiency is not due to nephrocalcinosis
- •6) If taking chronic pain medications (including narcotic pain medications/opioids), must be on a stable regimen for at least 21 days prior to Screening Visit 1, and be willing to maintain medications at the same stable dose(s) and schedule throughout the Placebo-controlled Treatment Period of the study. The dose must not exceed 60 mg oral morphine equivalents/day
- •7) Provide written informed consent or if a minor, provide written consent and have a legally authorized representative willing and able to provide written informed consent, after the nature of the study has been explained, and prior to any research-related procedures
- •8) Willing to provide access to prior medical records for the collection of biochemical and radiographic data and disease history
- •9) Females of child-bearing potential must have a negative urine pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not to be of childbearing potential include those who have been in menopause for at least two years prior to Screening, or have had tubal ligation at least one year prior to Screening, or have had a total hysterectomy or bilateral salpingo-oophorectomy
- •10) Participants of child bearing potential or with partners of child-bearing potential who have not undergone a total hysterectomy or bilateral salpingo - oophorectomy and are sexually active must consent to use two effective methods of contraception as determined by the site investigator (i.e. oral hormonal contraceptives, patch hormonal contraceptives, vaginal ring, intrauterine device, physical double-barrier methods, surgical hysterectomy, vasectomy, tubal ligation, or true abstinence) from the period following the signing of the informed consent through 12 weeks after last dose of study drug
排除标准
- •Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:
- •1) Use of a pharmacologic vitamin D metabolite or analog (calcitriol, doxercalciferol, and paricalcitol) within 14 days prior to Screening Visit 2
- •2) Use of oral phosphate within 14 days prior to Screening Visit 2
- •3) Use of aluminum hydroxide antacids, acetazolamides, and thiazides within 7 days prior to Screening Visit 2
- •4) Chronic use of systemic corticosteroids defined as more than 10 days in the 2 months prior to Screening Visit 1
- •5) Corrected serum calcium level = 10.8 mg/dL (2.7 mmol/L) at Screening Visit 2
- •6) Serum iPTH = 2.5 upper limit of normal (ULN) at Screening Visit 1
- •7) Use of medication to suppress PTH (cinacalcet, for example) within 60 days prior to Screening Visit 1
- •8) Use of bisphosphonates in the 2 years prior to Screening Visit 1
- •9) Use of denosumab in the 6 months prior to Screening Visit 1
- •10) Use of teriparatide in the 2 months prior to Screening Visit 1
- •11) Planned or recommended orthopedic surgery within the first 24 weeks of the clinical trial period
- •12) History of traumatic fracture or orthopedic surgery within 6 months prior to Screening Visit 1
- •13) Use of KRN23, or any other therapeutic monoclonal antibody within 90 days prior to Screening Visit 1
- •14) Use of any investigational product or investigational medical device within 30 days prior to Screening Visit 1, or requirement for any investigational agent prior to completion of all scheduled study assessments
- •OR, in Japan, use of any investigational product or investigational medical device within 4 months prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments
- •15) Pregnant or breastfeeding at Screening /Baseline or planning to become pregnant (self or partner) at any time during the study
- •16) Unable or unwilling to withhold prohibited medications throughout the study
- •17) Presence or history of any hypersensitivity, allergic or anaphylactic reactions to any monoclonal antibody or KRN23 excipients that, in the judgment of the investigator, places the subject at increased risk for adverse effects
- •18) Prior history of positive test for human immunodeficiency virus antibody, hepatitis B surface antigen, and/or hepatitis C antibody
- •19) History of recurrent infection (other than dental abscesses, which are known to be associated with XLH) or predisposition to infection, or of known immunodeficiency
- •20) Presence of malignant neoplasm (except basal cell carcinoma)
- •21) Presence of a concurrent disease or condition that would interfere with study participation or affect safety
- •22) Presence or history of any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study
研究者
相似试验
进行中（未招募）
1 期
A study to assess the benefit of treatment beyond progression with enzalutamide in men who are starting treatment with docetaxel after worsening of their prostate cancer when taking enzalutamide aloneMetastatic Castrate Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004711-50-BEAstellas Pharma Europe Ltd650
进行中（未招募）
不适用
A Study of LY2835219 Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerMedDRA version: 17.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerEUCTR2013-004728-13-FREli Lilly and Company550
进行中（未招募）
不适用
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168, a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).on-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV) with mild-to-moderate renal involvementMedDRA version: 17.0Level: PTClassification code 10047115Term: VasculitisSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-001222-15-SEChemoCentryx, Inc.60
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular CoagulatioSepsis and disseminated intravascular coagulation.MedDRA version: 9.1 Level: LLT Classification code 10040047 Term: SepsisMedDRA version: 9.1 Level: LLT Classification code 10013442 Term: Disseminated intravascular coagulationEUCTR2007-002035-81-GBArtisan Pharma, Inc.800
进行中（未招募）
1 期
A Study of abemaciclib Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerEUCTR2013-004728-13-DEEli Lilly and Company710